Here are a few of the most interesting Sio Gene Therapies (formerly Axovant) statistics and facts I was able to dig up including revenue totals and employee counts. As always, be sure to check back in the future as I will be updating this post as new and updated stats become available.
Sio Gene Therapies (formerly Axovant) Facts
- Website: Official Website
- Year Founded: 2014
- Headquarters: New York, NY
- Founder(s): Vivek Ramaswamy
- Current Chief Executive: Pavan Cheruvu
What is Sio Gene Therapies (formerly Axovant)?
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. (source)
Sio Gene Therapies (formerly Axovant) Employee Count
Number of Axovant Gene Therapies employees:
Last updated 6/1/19
Sio Gene Therapies (formerly Axovant) Revenue Totals
Axovant Gene Therapies annual annual net income:
- FY 2019: $129 million net loss
- FY 2018: $221 million net loss
- FY 2017: $180 million net loss
- FY 2016: $133 million net loss
- FY 2015: $21 million net loss